Clinical Study Results, Data Presentations, DMF Submissions, and Acquisition Agreements - Analyst Notes on Forest Laboratories, Incyte, Illumina, INSYS Therapeutics and AMRI

NEW YORK, June 5, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), Incyte Corporation (NASDAQ: INCY), Illumina Inc. (NASDAQ: ILMN), INSYS Therapeutics, Inc. (NASDAQ: INSY) and Albany Molecular Research Inc. (NASDAQ: AMRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3391-100free.

--
Forest Laboratories Inc. Analyst Notes
On May 30, 2014, Forest Laboratories Inc. (Forest Laboratories) announced that data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan has been published in the May 30, 2014 issue of The Lancet. According to the Company, the study met its primary and key secondary endpoints and demonstrated statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at 8 weeks in patients with hypertension. Commenting on these results, Thomas Giles, M.D., Professor of Medicine, Tulane University School of Medicine, stated, "These data indicate that the combinations of nebivolol and valsartan were effective at lowering blood pressure in patients with hypertension. To our knowledge, this is the first study to assess the efficacy and safety of a fixed-dose combination consisting of a beta-blocker and angiotensin II receptor blocker in hypertensive patients." The full analyst notes on Forest Laboratories are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/FRX/report.pdf

--
Incyte Corporation Analyst Notes
On June 2, 2014, Incyte Corporation (Incyte) announced that the Company has presented preliminary results from an ongoing Phase I/II study of INCB24360 its oral indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor, combined with ipilimumab in patients with unresectable or metastatic melanoma at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Incyte said that the initial findings show that the combination was generally well tolerated and produced evidence of clinical response. Incyte President and CEO, Hervé Hoppenot, stated, "The synergistic activity observed between INCB24360 and ipilimumab increases our confidence in the value of investigating other immunotherapy combinations with INCB24360 in multiple tumor types." The full analyst notes on Incyte are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/INCY/report.pdf

--
Illumina Inc. Analyst Notes
On June 2, 2014, Illumina Inc.'s (Illumina) stock went up by 0.27%, to $158.68 per share. In the last three days of trading, the Company's stock has gained 0.82%, compared to the Nasdaq Composite which has advanced 0.28%, during the same trading period. The full analyst notes on Illumina are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/ILMN/report.pdf

--
INSYS Therapeutics, Inc. Analyst Notes
On May 29, 2014, INSYS Therapeutics, Inc. (Insys Therapeutics) announced that the Company has submitted a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA). According to the Insys Therapeutics, the FDA submitted Type II DMF for the Company's cannabidiol (CBD) active pharmaceutical ingredient and has been issued DMF# 28255. The Company President and CEO Michael L. Babich, commented, "Advancing our pharmaceutical CBD program is one of our top priorities and the DMF brings us another step closer to filing an Investigational New Drug Application (IND) for CBD in the second half of 2014. We are pleased to submit this voluntary filing, which enables us to comply with regulatory requirements and demonstrate the safety, efficacy and quality of our CBD program." The full analyst notes on INSYS Therapeutics are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/INSY/report.pdf

--
Albany Molecular Research Inc. Analyst Notes
On June 2, 2014, Albany Molecular Research Inc. (AMRI) announced that the Company has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC (OsoBio) for $110 million in cash. According to AMRI, the acquisition along with associated fees are expected to be paid through cash currently held by the Company, and, subject to Hart-Scott-Rodino clearance and other conditions to closing, is expected to be completed by Q3 2014. AMRI President and CEO, William S. Marth, remarked, "The acquisition of OsoBio is highly complementary to our finished dose manufacturing business, and is consistent with our strategy to be the preeminent supplier of custom and complex drug development services and products to the pharmaceutical industry. In addition, we expect to realize savings in capital costs associated with the previously planned facility expansion." The full analyst notes on AMRI are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/AMRI/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review